Financial Performance - The group's unaudited revenue for the nine months ended September 30, 2019, was approximately SGD 5,426,000, a decrease of about SGD 7,000 or 0.1% compared to the same period in 2018[6]. - The group's unaudited profit for the nine months ended September 30, 2019, was approximately SGD 693,000, a decrease of about SGD 936,000 or 57.5% compared to the same period in 2018[6]. - Basic earnings per share for the nine months ended September 30, 2019, was 0.12 Singapore cents, down from 0.27 Singapore cents for the same period in 2018[6]. - The group's total comprehensive income attributable to owners for the nine months ended September 30, 2019, was SGD 693,000, compared to SGD 1,629,000 for the same period in 2018[10]. - Total revenue for the nine months ended September 30, 2019, was approximately SGD 5,426,000, a decrease of about SGD 7,000 or 0.1% compared to SGD 5,433,000 for the same period in 2018[41]. - The company reported a pre-tax profit of SGD 693,000 for the nine months ended September 30, 2019, compared to SGD 1,629,000 for the same period in 2018[34]. - Profit for the nine months ended September 30, 2019, was approximately SGD 693,000, a decrease of approximately SGD 936,000 compared to the profit of approximately SGD 1,629,000 for the same period in 2018[64]. Revenue Breakdown - Consultation services generated revenue of SGD 1,425,000, an increase of 3.4% compared to SGD 1,378,000 in the previous year[28]. - Treatment services revenue decreased to SGD 1,930,000 from SGD 2,145,000, reflecting a decline of approximately 10%[28]. - Prescription and dispensing services revenue was SGD 1,545,000, a slight decrease from SGD 1,561,000, indicating a decline of about 1%[28]. - The company reported a significant increase in revenue from other services, which rose to SGD 443,000 from SGD 349,000, marking a growth of approximately 27%[28]. - Revenue recognized at a point in time was SGD 1,988,000, compared to SGD 1,910,000 in the previous year, showing an increase of about 4.1%[28]. - Revenue recognized over time was SGD 3,438,000, down from SGD 3,523,000, indicating a decrease of approximately 2.4%[28]. - Revenue from consultation services increased by SGD 47,000 to SGD 1,425,000, with a total number of patients rising by 3.8% from 13,478 to 14,001[43]. - Revenue from treatment services decreased by SGD 215,000 to SGD 1,930,000, primarily due to a decline in income from injection and intense pulse light procedures[43]. Expenses and Costs - The group reported a gross profit margin decline due to increased employee benefits expenses and other operating costs[8]. - The group incurred total employee benefits expenses of SGD 1,504,000 for the nine months ended September 30, 2019, compared to SGD 1,151,000 for the same period in 2018[8]. - The cost of consumables and medical supplies for the nine months ended September 30, 2019, was SGD 839,000, a decrease from SGD 855,000 in the previous year, aligning with the reduction in revenue from prescription and dispensing services[44]. - The company incurred administrative expenses of SGD 225,000 for the nine months ended September 30, 2019, slightly down from SGD 233,000 in the same period of 2018[31]. - Other operating expenses increased by approximately SGD 119,000 or 8.6%, from SGD 1,381,000 for the nine months ended September 30, 2018, to SGD 1,500,000 for the same period in 2019[55]. - Professional and consultancy fees increased by approximately SGD 270,000, primarily related to professional fees payable to doctors[59]. - The company reported a net foreign exchange loss of SGD 186,000 for the nine months ended September 30, 2019, compared to SGD 90,000 in the previous year[31]. - Tax expenses decreased from approximately SGD 285,000 for the nine months ended September 30, 2018, to approximately SGD 210,000 for the same period in 2019, primarily due to a reduction in pre-tax profits[63]. Dividends and Shareholder Information - The board of directors did not recommend any dividend payment for the nine months ended September 30, 2019[6]. - The company did not recommend any dividends for the nine months ended September 30, 2019, consistent with the previous year[35]. - The company’s directors collectively hold 358,000,000 shares, representing 59.66% of the company's equity[66]. - As of September 30, 2019, Brisk Success holds 358,000,000 shares, representing 59.66% of the company's equity[69]. - Victory Spring Ventures Limited owns 35,560,000 shares, accounting for 5.93% of the company's equity[69]. - The company did not purchase, sell, or redeem any of its listed securities during the nine months ended September 30, 2019[76]. Corporate Governance and Compliance - The audit committee, consisting of three independent non-executive directors, reviewed the unaudited condensed consolidated financial statements for the nine months ended September 30, 2019[85]. - The company has complied with all applicable corporate governance code provisions during the nine months ended September 30, 2019[73]. - There were no interests held by directors or controlling shareholders in any competing businesses as of September 30, 2019[81]. - The company has not granted any rights to directors or their associates to benefit from acquiring shares or debt securities during the nine months ended September 30, 2019[77]. - The company has adopted a code of conduct for securities transactions by directors, which complies with GEM Listing Rules[78]. - No share options have been granted since the adoption of the share option scheme on September 22, 2017[75]. Future Outlook and Strategic Plans - The company aims to expand its business strategically in Singapore and target potential markets in Hong Kong and China to capture growing demand for dermatological and surgical services[38]. - The company plans to continue attracting and training therapists to enhance patient experience across various services, including medical aesthetics and skincare consultations[40]. - The company is considering strategic acquisitions to enhance its product offerings and market presence[87]. - Market expansion plans include entering two new regions, which are projected to increase market share by 5%[87]. - The company is investing in new technology development, with a budget allocation of $2 million for R&D initiatives[87]. - Cost management strategies have been implemented, aiming for a 3% reduction in operational expenses[87]. - Overall, the company remains optimistic about sustaining growth and enhancing shareholder value in the coming quarters[87]. - The company has provided a positive outlook for the next quarter, projecting a revenue increase of 10% to 15%[87]. - New product launches are expected to contribute an additional $5 million in revenue for the upcoming quarter[87]. - User data shows a growth in active users by 15% year-over-year, reaching a total of 2.5 million active users[87]. - The company reported a net profit margin of 20% for the third quarter, maintaining strong profitability[87]. - The third quarter performance report indicates a significant increase in revenue compared to the previous quarter, reflecting a strong market demand[87]. Accounting Policies - The company has adopted IFRS 16, which impacts the accounting for leases, recognizing right-of-use assets and lease liabilities[16]. - The financial assets are measured at amortized cost if the business model is to hold the financial assets to collect contractual cash flows[19]. - The company has confirmed expected credit losses for trade receivables based on historical loss experience and adjusted for various factors, reflecting a proactive approach to credit risk management[20]. - The decrease in rental and property maintenance expenses was attributed to the application of IFRS 16, which replaced straight-line operating lease expenses with depreciation and interest expenses on lease liabilities[58].

Financial Performance - The group's unaudited revenue for the six months ended June 30, 2019, was approximately SGD 3,471,000, a decrease of about SGD 240,000 or 6.5% compared to the same period in 2018[6]. - The group's unaudited profit for the six months ended June 30, 2019, was approximately SGD 333,000, a decrease of about SGD 797,000 or 70.5% compared to the same period in 2018[6]. - Basic earnings per share for the six months ended June 30, 2019, was 0.06 Singapore cents, down from 0.22 Singapore cents for the same period in 2018[6]. - Total revenue for the six months ended June 30, 2019, was SGD 3,471,000, a decrease of 6.5% compared to SGD 3,711,000 for the same period in 2018[35]. - The company reported a net profit attributable to owners of SGD 333,000 for the six months ended June 30, 2019, compared to SGD 1,130,000 for the same period in 2018, reflecting a significant decline[44]. - The net cash from operating activities for the six months ended June 30, 2019, was approximately SGD 359,000, down from SGD 802,000 for the same period in 2018[107]. - The group reported a pre-tax profit of SGD 473,000 for the six months ended June 30, 2019, compared to SGD 1,320,000 for the same period in 2018[16]. - Other income, including interest income and government grants, totaled SGD 226,000 for the six months ended June 30, 2019, compared to SGD 44,000 in the same period of 2018[39]. Assets and Liabilities - Total assets less current liabilities as of June 30, 2019, amounted to SGD 15,810,000, compared to SGD 14,630,000 as of December 31, 2018[11]. - The total equity as of June 30, 2019, was SGD 14,939,000, an increase from SGD 14,606,000 as of December 31, 2018[11]. - Cash and cash equivalents at the end of the period were SGD 12,974,000, down from SGD 14,128,000 at the beginning of the period[16]. - The company’s total assets included right-of-use assets valued at SGD 1,612,000 as of June 30, 2019[50]. - Trade receivables increased to SGD 569,000 as of June 30, 2019, compared to SGD 481,000 as of December 31, 2018[51]. - Trade payables increased to SGD 176,000 as of June 30, 2019, from SGD 99,000 as of December 31, 2018[64]. - Deferred revenue at the end of the reporting period was SGD 72,000, reflecting prepayments received from customers[62]. Revenue Breakdown - Revenue from consultation services was SGD 926,000, while prescription and dispensing services generated SGD 985,000, and treatment services accounted for SGD 1,286,000[35]. - Revenue from consultation services decreased from SGD 969,000 to SGD 926,000, with the total number of patients dropping from 9,369 to 8,940, a decline of 4.6%[81]. - Revenue from prescription and dispensing services fell from SGD 1,094,000 to SGD 985,000, primarily due to reduced profits from patients purchasing DS brand skincare products without consulting a doctor[81]. - Revenue from treatment services decreased from SGD 1,395,000 to SGD 1,286,000, attributed to a decline in procedures involving anesthesia and intense pulse light[81]. Corporate Governance - The company has complied with all applicable corporate governance codes during the six months ending June 30, 2019[136]. - The board of directors has confirmed compliance with the trading rules for directors throughout the six-month period ending June 30, 2019[142]. - The company is committed to high standards of corporate governance to manage business risks and enhance transparency[136]. - The audit committee was established on September 22, 2017, and consists of three independent non-executive directors[147]. - The audit committee's main responsibilities include reviewing the company's financial reporting procedures and internal control systems[150]. Employee and Operational Changes - Total employee costs increased to SGD 956,000 from SGD 759,000, mainly due to the hiring of additional staff at beauty clinics and the "Family and Skin" clinic[86]. - The total number of employees increased to 32 from 22, reflecting the company's expansion efforts[89]. - The group has increased its workforce to 32 employees as of June 30, 2019, up from 20 employees as of December 31, 2018[116]. - The company plans to recruit an additional dermatologist as part of its expansion strategy[77]. Strategic Plans - The company plans to expand its market share in the dermatology and surgery services sector in Singapore, focusing on enhancing its brand reputation[77]. - The company is negotiating to renovate its existing East Coast clinic and open a new medical beauty clinic in the same area[77]. - The group plans to establish new medical aesthetic clinics and enhance existing clinic services, with a budget allocation of approximately HKD 13.6 million for this purpose[120]. Accounting Policies - The financial statements for the six months ended June 30, 2019, were prepared in accordance with International Financial Reporting Standards and the GEM Listing Rules[23]. - The company adopted IFRS 16 Leases effective January 1, 2019, which introduced a single accounting model for lessees, recognizing right-of-use assets and lease liabilities[22]. - The financial statements were prepared on a historical cost basis, reflecting fair value based on the consideration exchanged for goods or services[23]. - The company recognizes expected credit losses for trade receivables based on historical credit loss experience and adjusts for current and forecasted economic conditions[26]. Shareholder Information - As of June 30, 2019, Loh Teck Hiong, Ee Hock Leong, and Dr. Ko each hold 358,000,000 shares, representing 59.66% of the company's equity[128]. - Brisk Success, owned by Loh, Ee, and Dr. Ko, holds 358,000,000 shares, accounting for 59.66% of the company's equity[132]. - Victory Spring Ventures Limited holds 35,560,000 shares, representing 5.93% of the company's equity[132]. - The company has not granted any share options since the adoption of the share option plan on September 22, 2017[139].

Financial Performance - The group's unaudited revenue for the three months ended March 31, 2019, was approximately SGD 1,762,000, a decrease of about SGD 63,000 or 3.5% compared to the same period in 2018[5]. - The group's unaudited profit for the three months ended March 31, 2019, was approximately SGD 298,000, an increase of about SGD 5,000 or 1.7% compared to the same period in 2018[5]. - Basic earnings per share for the three months ended March 31, 2019, remained at 0.05 Singapore cents, unchanged from the same period in 2018[5]. - The group's pre-tax profit for the three months ended March 31, 2019, was SGD 368,000, compared to SGD 388,000 for the same period in 2018[7]. - Total comprehensive income attributable to owners of the company for the three months ended March 31, 2019, was SGD 298,000, compared to SGD 293,000 for the same period in 2018[7]. - The total revenue for the first quarter of 2019 was approximately SGD 1,762,000, a decrease of about SGD 63,000 or 3.5% compared to SGD 1,825,000 in the same period of 2018[48]. - The company reported a pre-tax profit of SGD 298,000 for the first quarter of 2019, compared to SGD 293,000 in the same period of 2018[45]. - Profit for the three months ended March 31, 2019, was approximately SGD 298,000, a decrease of about SGD 5,000 compared to SGD 293,000 for the same period in 2018[75]. Revenue Breakdown - Revenue from consultation services was SGD 488,000, accounting for 27.7% of total revenue, while prescription and dispensing services generated SGD 495,000, representing 28.1%[48]. - Revenue from consultation services increased by approximately SGD 25,000 to about SGD 488,000, with the total number of patients rising from 5,239 to 5,587, representing a growth of 6.6%[57]. - Revenue from prescription and dispensing services decreased by approximately SGD 69,000 to SGD 495,000, primarily due to reduced sales of DS brand skincare products[57]. - Revenue from treatment services decreased by SGD 20,000 to approximately SGD 658,000, mainly due to a decline in procedures involving anesthesia and intense pulse light[57]. Operating Expenses and Tax - The group incurred total operating expenses of SGD 614,000 for the three months ended March 31, 2019, down from SGD 708,000 in the same period in 2018[7]. - The group’s tax expense for the three months ended March 31, 2019, was SGD 70,000, compared to SGD 95,000 for the same period in 2018[7]. - Tax expenses for the three months ended March 31, 2019, were approximately SGD 70,000, down from SGD 95,000 for the same period in 2018, mainly due to a decrease in pre-tax profit[74]. Corporate Governance - The board of directors did not recommend any dividend payment for the three months ended March 31, 2019[5]. - The company did not declare any dividends for the quarter ending March 31, 2019, consistent with the previous year[46]. - The board of directors confirmed compliance with the trading code for directors during the three months ended March 31, 2019[92]. - The company has adopted the corporate governance code as per GEM Listing Rules and has complied with all applicable provisions during the reporting period[86]. - The board is committed to maintaining high standards of corporate governance to enhance transparency and accountability[86]. Market Expansion and Strategy - The company plans to expand its market share in the dermatology and surgical services sector in Singapore, focusing on enhancing its brand and business growth[51]. - A new medical aesthetic clinic was opened in February 2019 at the same property as the existing Orchard Clinic, aimed at developing the medical aesthetic business[51]. - The company is seeking to expand the "Family and Skin" clinics, which will focus on treating less complex skin conditions, thereby increasing patient referrals to existing clinics for more complex treatments[52]. Shareholding and Interests - As of March 31, 2019, Loh Teck Hiong, Ee Hock Leong, and Koh Yong Jian collectively own 358,000,000 shares, representing 59.66% of the company's equity[77]. - Brisk Success Holdings Limited, controlled by the aforementioned individuals, holds the 358,000,000 shares, with each individual having a beneficial ownership of approximately 33.33%[82]. - Victory Spring Ventures Limited holds 35,560,000 shares, accounting for 5.93% of the company's equity, with Ye Zhi Chun as the beneficial owner[81]. - The company has not issued any share options since the adoption of the share option plan on September 22, 2017[87]. - No shares were purchased, sold, or redeemed by the company or its subsidiaries during the three months ended March 31, 2019[90]. Compliance and Audit - The audit committee, established on September 22, 2017, consists of three independent non-executive directors and is responsible for reviewing the company's financial reporting procedures and internal control systems[100]. - As of March 31, 2019, there were no interests held by the company's directors or controlling shareholders in any business that competes or may compete with the group[95]. - The compliance advisor confirmed that, as of March 31, 2019, there were no interests related to the group that needed to be disclosed under GEM Listing Rules[96]. - The independent non-executive directors reviewed the implementation of the non-competition agreement and found compliance by the controlling shareholders for the three months ended March 31, 2019[94].

Financial Performance - The group's revenue for the year ended December 31, 2018, decreased to approximately SGD 6,987,000, a decline of about 0.9% compared to SGD 7,054,000 for the year ended December 31, 2017[10]. - The group recorded a profit of approximately SGD 1,851,000 for the year ended December 31, 2018, an increase of about SGD 2,321,000 compared to a loss of SGD 470,000 for the year ended December 31, 2017[11]. - The group's total revenue for the year ended December 31, 2018, was approximately SGD 6,987,000, a slight decrease of SGD 67,000 or 0.9% compared to SGD 7,054,000 for the year ended December 31, 2017[21]. - Revenue from consultation services increased from SGD 1,794,000 to SGD 1,837,000, representing a growth of 2.4%[22]. - Revenue from prescription and dispensing services rose from SGD 1,956,000 to SGD 2,065,000, an increase of 5.6%[23]. - Revenue from treatment services decreased from SGD 2,821,000 to SGD 2,648,000, a decline of 6.1% primarily due to reduced demand for certain procedures[23]. - The total number of patient consultations increased by 1.2%, from 21,368 to 21,344, indicating stable patient engagement despite revenue fluctuations[21]. Business Expansion and Strategy - The group plans to strategically expand its business by establishing new clinics in Orchard and Raffles Place, as well as a new medical beauty clinic near Orchard Clinic[12]. - The group will continue to review its business strategies to identify opportunities for expansion and customer base growth[12]. - The company plans to expand its market share in the dermatology and surgical services sector in Singapore, capitalizing on the growing interest in medical aesthetic services[17]. - A new medical aesthetic clinic is set to open in February 2019, leveraging the existing Orchard Clinic's location to enhance service offerings[18]. - The Raffles Place Clinic has relocated to a larger property, with operations commencing at the end of February 2019, aimed at improving service capacity[18]. Operational Efficiency and Cost Management - The group aims to manage expenses by enhancing employee skills to reduce labor costs and leveraging technology to decrease labor intensity[12]. - The increase in costs is attributed to higher operational expenses post-listing, including compliance and professional fees[11]. - The group is focused on optimizing operations and enhancing overall business efficiency through the opening of new clinics[12]. - Total operating expenses increased by approximately 348,000 SGD or 22.5% from 1,546,000 SGD for the year ended December 31, 2017, to 1,894,000 SGD for the year ended December 31, 2018[33]. - Employee benefits expenses increased from SGD 1,350,000 to SGD 1,812,000, reflecting higher salaries and bonuses due to company growth[28]. - The total number of employees (excluding doctors) rose from 18 to 20, indicating a slight increase in workforce to support business expansion[29]. Financial Position and Equity - The group had no bank borrowings or interest-bearing liabilities as of December 31, 2018, resulting in a decrease in financial costs by approximately 16,000 SGD[38]. - The total equity of the group as of December 31, 2018, was approximately 14,606,000 SGD, up from approximately 12,755,000 SGD as of December 31, 2017[43]. - Cash and cash equivalents amounted to approximately 14,128,000 SGD as of December 31, 2018, compared to approximately 12,553,000 SGD as of December 31, 2017[43]. - The group incurred a one-time listing expense of approximately 2,933,000 SGD for the year ended December 31, 2017, with no listing expenses incurred for the year ended December 31, 2018[39]. - Employee costs, including directors' remuneration, were approximately 1,812,000 SGD for the year ended December 31, 2018, compared to approximately 1,350,000 SGD for the year ended December 31, 2017[51]. Corporate Governance and Compliance - The company has confirmed compliance with regulatory requirements, with no significant violations reported as of the report date[59]. - The company has adopted the corporate governance code as per GEM listing rules, ensuring compliance with applicable governance standards[164]. - The company has maintained a high level of corporate governance to manage business risks and enhance transparency[163]. - The company has implemented adequate internal control systems and risk management procedures[169]. - The board consists of six members, including three executive directors and three independent non-executive directors[166]. - The company has established a compliance advisory agreement with Chiu Yau Capital Limited effective from November 1, 2017[128]. Shareholding and Ownership Structure - As of December 31, 2018, Dr. Loh Teck Hiong, Dr. Ee Hock Leong, and Dr. Ko Yong Jian each hold 358,000,000 shares, representing 59.66% of the company's equity[104]. - Brisk Success Holdings Limited, which is controlled by the aforementioned doctors, holds the same number of shares, indicating a consolidated ownership structure[108]. - Victory Spring Ventures Limited holds 35,560,000 shares, accounting for 5.93% of the company's equity[108]. - The total number of shares available for issuance under the share option scheme is capped at 10% of the total issued shares at the time of listing, which amounts to a maximum of 60,000,000 shares[116]. - The maximum number of shares that can be issued to any participant under the share option scheme in any 12-month period is limited to 1% of the total issued shares[118]. Risks and Challenges - The company faces significant business risks related to the recruitment and retention of skilled professionals, which could adversely affect financial performance[56]. - The dermatology and skincare services industry is sensitive to negative media reports, which may impact consumer confidence and market perception[57]. Future Plans and Investments - The planned use of the net proceeds includes strategic expansion and enhancement of the clinic network in Singapore, with an allocation of HKD 14.1 million[64]. - Establishing new medical beauty clinics has an allocated budget of HKD 13.6 million, with HKD 10.4 million already utilized[64]. - The purchase of additional new equipment and expansion of treatment and product offerings is budgeted at HKD 9.6 million[64]. - A centralized logistics center is planned with an allocation of HKD 2.3 million, although the project has been delayed due to space acquisition issues[64][68]. - Improvement of IT infrastructure and systems has a budget of HKD 2.4 million, with ongoing efforts to find suitable systems[64][69].